Danaher boosts dividends for 13 years with strong financials and steady growth potential.

Danaher, a leading American healthcare company specializing in biotechnology, life sciences, and diagnostics, has increased its dividend for 13 consecutive years, showcasing impressive dividend growth. The company maintains a solid financial position with a low long-term debt-to-equity ratio of 0.3 and a high interest coverage ratio of 17. Its price-to-earnings ratio stands at 24.4 based on adjusted earnings, reflecting its historically high valuation multiples. With a market cap of $128 billion and a workforce of 59,000, Danaher remains a significant player in the life sciences sector, attracting investors focused on dividend growth and financial stability.